Key Takeaways
- • FDA announced on April 28, 2026, two proof-of-concept real-time clinical trials (RTCTs)—one Phase 2 multi-site trial for treatment-naïve mantle cell lymphoma and one Phase 1b trial for limited-stage small cell lung carcinoma—designed to report endpoints and data signals to regulators in real-time.
- • The agency issued a Request for Information (RFI) on April 29, 2026, soliciting feedback on a proposed pilot program to integrate artificial intelligence and AI-enabled technologies into early-phase clinical trials to improve efficiency, speed, safety monitoring, dose selection, and go/no-go decision-making.
- • The initiative aims to reduce traditional "hiatuses" between clinical trial phases by enabling continuous trials, potentially accelerating time-to-market for promising therapies while maintaining human subject protections and regulatory compliance.
- • Comment deadline for the RFI is May 29, 2026; FDA plans to announce final selection criteria in July 2026 and complete pilot selections by August 2026, with implications for PDUFA reauthorization negotiations.
- • Companies will need to reconsider clinical trial strategy, including multi-regulatory authorization planning and extended patient monitoring protocols, to align with real-time reporting requirements and compressed phase transitions.
Summary
The FDA is advancing a modernized drug development framework centered on real-time clinical trials and artificial intelligence integration. On April 28, 2026, the agency announced the successful initiation of two proof-of-concept RTCTs alongside a formal RFI seeking industry input on a broader AI-focused pilot program. This dual announcement signals the FDA's commitment to harnessing technological advances to accelerate drug development timelines while maintaining regulatory rigor.
The two proof-of-concept trials represent different therapeutic areas and development stages. The first is a Phase 2 multi-site trial for patients with treatment-naïve mantle cell lymphoma, while the second is a Phase 1b trial for limited-stage small cell lung carcinoma, with final site selection ongoing. Both trials will transmit endpoints and data signals to the FDA in real-time, eliminating traditional reporting delays and enabling regulators to monitor trial progress continuously. This paradigm shift directly addresses one of the agency's core objectives: eliminating the informational "hiatuses" that typically occur between clinical trial phases.
The RFI, published in the Federal Register on April 29, 2026, invites stakeholder feedback on a proposed pilot program to optimize early-phase clinical trials using AI and AI-enabled technologies. The pilot will assess whether artificial intelligence can enhance trial efficiency, strengthen safety monitoring capabilities, support dose selection decisions, and enable faster, more informed regulatory go/no-go determinations. The FDA is actively soliciting input on program design, implementation frameworks, evaluation metrics, and success criteria, indicating a consultative approach to pilot development.
Regulatory and operational complexity will be significant. Companies undertaking RTCTs must navigate real-time reporting protocols, adapt human subject protection frameworks to accommodate compressed trial phase intervals, and recalibrate multi-regulatory authorization strategies. Extended patient monitoring may become standard practice given the elimination of traditional gaps between phases. The May 29, 2026, comment deadline allows stakeholders a one-month window to provide input. FDA plans to release final selection criteria in July 2026 and complete pilot selections in August 2026.
These FDA initiatives are expected to become central topics in upcoming Prescription Drug User Fee Act (PDUFA) reauthorization discussions, reflecting broader industry recognition that modernizing early-phase trial efficiency could materially reduce development timelines and costs for pharmaceutical companies and biotech sponsors.
The two proof-of-concept trials represent different therapeutic areas and development stages. The first is a Phase 2 multi-site trial for patients with treatment-naïve mantle cell lymphoma, while the second is a Phase 1b trial for limited-stage small cell lung carcinoma, with final site selection ongoing. Both trials will transmit endpoints and data signals to the FDA in real-time, eliminating traditional reporting delays and enabling regulators to monitor trial progress continuously. This paradigm shift directly addresses one of the agency's core objectives: eliminating the informational "hiatuses" that typically occur between clinical trial phases.
The RFI, published in the Federal Register on April 29, 2026, invites stakeholder feedback on a proposed pilot program to optimize early-phase clinical trials using AI and AI-enabled technologies. The pilot will assess whether artificial intelligence can enhance trial efficiency, strengthen safety monitoring capabilities, support dose selection decisions, and enable faster, more informed regulatory go/no-go determinations. The FDA is actively soliciting input on program design, implementation frameworks, evaluation metrics, and success criteria, indicating a consultative approach to pilot development.
Regulatory and operational complexity will be significant. Companies undertaking RTCTs must navigate real-time reporting protocols, adapt human subject protection frameworks to accommodate compressed trial phase intervals, and recalibrate multi-regulatory authorization strategies. Extended patient monitoring may become standard practice given the elimination of traditional gaps between phases. The May 29, 2026, comment deadline allows stakeholders a one-month window to provide input. FDA plans to release final selection criteria in July 2026 and complete pilot selections in August 2026.
These FDA initiatives are expected to become central topics in upcoming Prescription Drug User Fee Act (PDUFA) reauthorization discussions, reflecting broader industry recognition that modernizing early-phase trial efficiency could materially reduce development timelines and costs for pharmaceutical companies and biotech sponsors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.